We are live on ! Find out more
PTGX icon

Protagonist Therapeutics
PTGX

185 hedge funds and large institutions have $1.73B invested in Protagonist Therapeutics in 2024 Q1 according to their latest regulatory filings, with 49 funds opening new positions, 61 increasing their positions, 57 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

145% more first-time investments, than exits

New positions opened: 49 | Existing positions closed: 20

29% more capital invested

Capital invested by funds: $1.34B → $1.73B (+$390M)

19% more funds holding

Funds holding: 156 → 185 (+29)

1.22% more ownership

Funds ownership: 101.69% → 102.91% (+1.2%)

7% more repeat investments, than reductions

Existing positions increased: 61 | Existing positions reduced: 57

14% less funds holding in top 10

Funds holding in top 10: 7 → 6 (-1)

83% less call options, than puts

Call options by funds: $1.14M | Put options by funds: $6.85M

Holders
185
Holders Change
+29
Holders Change %
+18.59%
% of All Funds
2.66%
Holding in Top 10
6
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-14.29%
% of All Funds
0.09%
New
49
Increased
61
Reduced
57
Closed
20
Calls
$1.14M
Puts
$6.85M
Net Calls
-$5.71M
Net Calls Change
-$17.8M

Top Buyers

1
CAC
Cowen and Company
New York
+$42.4M
2
FFM
Fairmount Funds Management
Pennsylvania
+$25.4M
3
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$25.2M
4
Marshall Wace
Marshall Wace
United Kingdom
+$22.7M
5
WP
Woodline Partners
California
+$17.3M

Top Sellers

1
BI
BVF Inc
California
-$54.1M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
-$38.5M
3
KCM
Kynam Capital Management
New Jersey
-$23.4M
4
Morgan Stanley
Morgan Stanley
New York
-$13.7M
5
SC
Stempoint Capital
New York
-$11.8M
Name Holding Trade Value Shares
Change 		Change in
Stake
FCM
1
Farallon Capital Management
California
$166M +$124K +4,543 +0.1%
BlackRock
2
BlackRock
New York
$161M +$696K +25,583 +0.5%
RI
3
RTW Investments
New York
$154M – – –
BI
4
BVF Inc
California
$109M -$54.1M -1,988,858 -35%
State Street
5
State Street
Massachusetts
$94.7M +$14.8M +542,556 +20%
Vanguard Group
6
Vanguard Group
Pennsylvania
$92.4M +$1.06M +39,055 +1%
JJ
7
Johnson & Johnson
New Jersey
$70.9M – – –
Adage Capital Partners
8
Adage Capital Partners
Massachusetts
$64.2M +$25.2M +927,167 +72%
Morgan Stanley
9
Morgan Stanley
New York
$54.4M -$13.7M -503,796 -21%
CAC
10
Cowen and Company
New York
$45.1M +$42.4M +1,557,636 New
Geode Capital Management
11
Geode Capital Management
Massachusetts
$37.4M +$1.24M +45,455 +4%
Point72 Asset Management
12
Point72 Asset Management
Connecticut
$34.7M -$38.5M -1,413,551 -54%
JFG
13
Jefferies Financial Group
New York
$34.2M -$2.45M -90,000 -7%
KCM
14
Kynam Capital Management
New Jersey
$33.1M -$23.4M -860,633 -43%
PA
15
Perceptive Advisors
New York
$28.8M +$16.6M +611,063 +159%
Marshall Wace
16
Marshall Wace
United Kingdom
$28.3M +$22.7M +834,423 +586%
FFM
17
Fairmount Funds Management
Pennsylvania
$27M +$25.4M +931,890 New
Deutsche Bank
18
Deutsche Bank
Germany
$26.3M +$21.6K +794 +0.1%
T. Rowe Price Associates
19
T. Rowe Price Associates
Maryland
$23.7M -$121K -4,444 -0.5%
Dimensional Fund Advisors
20
Dimensional Fund Advisors
Texas
$22.9M -$685K -25,193 -3%
ACM
21
ADAR1 Capital Management
Texas
$22.7M +$15.9M +584,796 +291%
6CM
22
683 Capital Management
New York
$20.3M -$408K -15,000 -2%
N
23
Nuveen
North Carolina
$19.6M +$10.1M +372,782 +122%
WP
24
Woodline Partners
California
$18.4M +$17.3M +636,956 New
DCM
25
Driehaus Capital Management
Illinois
$16.2M +$9.85M +361,841 +182%
1
2 3 4 5

PTGX Hedge Fund Activity: Q1 2024 in Review

185 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Protagonist Therapeutics (PTGX) for Q1 2024, worth a combined $1.73B — up 29% from $1.34B a quarter earlier.

Buyers outnumbered sellers: 49 funds opened new PTGX positions and 20 closed out — a net gain of 29 holders — while 61 added to existing stakes and 57 trimmed.

The largest buyer was Cowen and Company, opening a new position worth an estimated $42.4M. The largest seller was BVF Inc, cutting an estimated $54.1M.

  • 185 institutional investors held Protagonist Therapeutics (PTGX) as of Q1 2024, up from 156 in Q4 2023.
  • Funds reported $1.73B of Protagonist Therapeutics stock for Q1 2024, up 29% quarter-over-quarter.
  • 49 funds opened new Protagonist Therapeutics positions in Q1 2024 and 20 closed out, a net change of +29 holders.
  • The largest Protagonist Therapeutics buyer in Q1 2024 was Cowen and Company, an estimated $42.4M added.
  • The largest Protagonist Therapeutics seller in Q1 2024 was BVF Inc, an estimated $54.1M sold.

Based on aggregated 13F filings for Q1 2024.